References
- Ciccolini J , GrossE, DahanL, LacarelleB, MercierC. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin. Colorectal Cancer9(4) , 224–228 (2010).
- Gilbert JA , SalavaggioneOE, JiY et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. 12(6) , 1794–1803 (2006).
- Gupta N , AhmedI, SteinbergH, PatelD, Nissel-HorowitzS, MehrotraB. Gemcitabine-induced pulmonary toxicity: case report and review of the literature. Am. J. Clin. Oncol.25(1) , 96–100 (2002).
- Yonemori K , UenoH, OkusakaT et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res. 11(7) , 2620–2624 (2005).
- Mercier C , RaynalC, DahanL et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet. Genomics 17(10) , 841–844 (2007).
- Sugiyama E , KaniwaN, KimSR et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25(1) , 32–42 (2007).
- Maring JG , WachtersFM, SlijferM et al. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur. J. Clin. Pharmacol. 66(6) , 611–617 (2010).
- Farrell JJ , BaeK, WongJ, GuhaC, DickerAP, ElsalehH. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J.12(5) , 395–403 (2012).
- Ciccolini J , DahanL, AndreN et al. Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. J. Clin. Oncol. 28(1) , 160–165 (2010).
- Ciccolini J , MercierC, DahanL, AndreN. Integrating pharmacogenetics into gemcitabine dosing – time for a change? Nat. Rev. Clin. Oncol.8(7) , 439–444 (2011).
- Raynal C , CiccoliniJ, MercierC et al. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine. Ther. Drug Monit. 32(1) , 53–60 (2010).
- Tibaldi C , GiovannettiE, VasileE et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 14(6) , 1797–1803 (2008).
- Dahan L , CiccoliniJ, MercierC et al. Treatment failure upon gemcitabine intake. Is cytidine deaminase extensivity the ideal culprit? J. Clin. Oncol. 28(Suppl.) Abstract e14558 (2010).
- Mahlknecht U , Dransfeld Cl, Bulut N et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival. Leukemia23(10) , 1929–1932 (2009).
- Abraham A , VaratharajanS, AbbasS et al. Cytidine deaminase genetic variants influence RNA expression and cytarabine cytotoxicity in acute myeloid leukemia. Pharmacogenomics 13(3) , 269–282 (2012).
- Ciccolini J , EvrardA, M‘BatchiL et al. CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations. Pharmacogenomics 13(4) , 393–397 (2012).
- Serdjebi C , CiccoliniJ, EvrardA et al. Severe toxicities in patients undergoing gemcitabine, ARA-C, capecitabine, or azacytidine treatments: is deregulated cytidine deaminase the bad guy. Cancer Res. 72(8 Suppl. 1) Abstract 1869 (2012).
- Mercier C , DupuisC, BlesiusA et al. Early severe toxicities after capecitabine intake: possible implication of a cytidine deaminase extensive metabolizer profile. Cancer Chemother. Pharmacol. 63(6) , 1177–1180 (2009).
- Caronia D , MartinM, SastreJ et al. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand–foot syndrome. Clin. Cancer Res. 17(7) , 2006–2013 (2011).
- Fitzgerald SM , GoyalRK, OsborneWR, RoyJD, WilsonJW, FerrellRE. Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum. Genet.119(3) , 276–283 (2006).